InSphero

InSphero provides superior biological relevance to in vitro testing with easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. Our patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain, and skin.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDTECH

MEDTRONIC EXPANDS MINIMALLY INVASIVE SPINE SURGERY ECOSYSTEM WITH NEXT-GENERATION SPINAL TECHNOLOGIES

Medtronic plc | October 01, 2021

news image

Medtronic plc, the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery ecosystem, making it the only company to combine spinal implants, biologics, navigation, robotics, and AI-powered data to surgeons and patients. New additions to the Medtronic MIS+ portfolio include: Catalyft™ PL and PL40, the first releases in the new Catalyft™ Expandable Interbody System. Catalyft™ ...

Read More

CELL AND GENE THERAPY

BEIGENE INITIATES FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL OF INVESTIGATIONAL TYK2 INHIBITOR BGB-23339

BeiGene | November 23, 2021

news image

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor internally developed by BeiGene scientists. TYK2 is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways implicated in multiple immune-mediated disorders, such as psor...

Read More

PALO ALTO-BASED BIOTECH STARTUP TO MASS MANUFACTURE CLINICAL-GRADE IPSCS FOR CELL THERAPY

I Peace, Inc. | July 16, 2020

news image

I Peace, Inc. (CEO: Koji Tanabe, https://ipeace.com/), a Palo Alto-based biotech startup focusing on Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs) has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-size closed cassette. The system was developed in collaboration with FANUC CORPORATION (Head Office: Oshino, Yamanashi Prefecture, Japan; CEO: Kenji Yamaguchi). The technology is modular and scalable with a small foot...

Read More

INDUSTRIAL IMPACT

ETHERNA ANNOUNCES RESEARCH AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY TO ACCESS MRNA TECHNOLOGIES

eTheRNA | February 04, 2022

news image

eTheRNA immunotherapies NV ("eTheRNA") is pleased to announce the start of a strategic partnership with Merck KGaA, Darmstadt, Germany with the signing of a Research Agreement. The partnership will investigate the application of eTheRNA's proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck KGaA, Darmstadt, Germany. The ongoing pandemic has underlined the capability for mRNA vaccines as a new therapeutic modality. eTheRNA an...

Read More
news image

MEDTECH

MEDTRONIC EXPANDS MINIMALLY INVASIVE SPINE SURGERY ECOSYSTEM WITH NEXT-GENERATION SPINAL TECHNOLOGIES

Medtronic plc | October 01, 2021

Medtronic plc, the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery ecosystem, making it the only company to combine spinal implants, biologics, navigation, robotics, and AI-powered data to surgeons and patients. New additions to the Medtronic MIS+ portfolio include: Catalyft™ PL and PL40, the first releases in the new Catalyft™ Expandable Interbody System. Catalyft™ ...

Read More
news image

CELL AND GENE THERAPY

BEIGENE INITIATES FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL OF INVESTIGATIONAL TYK2 INHIBITOR BGB-23339

BeiGene | November 23, 2021

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor internally developed by BeiGene scientists. TYK2 is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways implicated in multiple immune-mediated disorders, such as psor...

Read More
news image

PALO ALTO-BASED BIOTECH STARTUP TO MASS MANUFACTURE CLINICAL-GRADE IPSCS FOR CELL THERAPY

I Peace, Inc. | July 16, 2020

I Peace, Inc. (CEO: Koji Tanabe, https://ipeace.com/), a Palo Alto-based biotech startup focusing on Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs) has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-size closed cassette. The system was developed in collaboration with FANUC CORPORATION (Head Office: Oshino, Yamanashi Prefecture, Japan; CEO: Kenji Yamaguchi). The technology is modular and scalable with a small foot...

Read More
news image

INDUSTRIAL IMPACT

ETHERNA ANNOUNCES RESEARCH AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY TO ACCESS MRNA TECHNOLOGIES

eTheRNA | February 04, 2022

eTheRNA immunotherapies NV ("eTheRNA") is pleased to announce the start of a strategic partnership with Merck KGaA, Darmstadt, Germany with the signing of a Research Agreement. The partnership will investigate the application of eTheRNA's proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck KGaA, Darmstadt, Germany. The ongoing pandemic has underlined the capability for mRNA vaccines as a new therapeutic modality. eTheRNA an...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us